Birgit Frauscher1, Poul Jennum, Yo-El S Ju, Ronald B Postuma, Isabelle Arnulf, Valerie Cochen De Cock, Yves Dauvilliers, Maria L Fantini, Luigi Ferini-Strambi, David Gabelia, Alex Iranzo, Smaranda Leu-Semenescu, Thomas Mitterling, Masayuki Miyamoto, Tomoyuki Miyamoto, Jacques Y Montplaisir, Wolfgang Oertel, Amélie Pelletier, Paolo Prunetti, Monica Puligheddu, Joan Santamaria, Karel Sonka, Marcus Unger, Christina Wolfson, Marco Zucconi, Michele Terzaghi, Birgit Högl, Geert Mayer, Raffaele Manni. 1. From the Department of Neurology (B.F., D.G., T.M., B.H.), Innsbruck Medical University, Austria; Danish Center for Sleep Medicine (P.J.), University of Copenhagen, Denmark; Department of Neurology (Y.-E.S.J.), Washington University School of Medicine, St Louis, MO; Department of Neurology (R.B.P.), McGill University, Montreal General Hospital, Canada; Unité des Pathologies du Sommeil (I.A., S.L.-S.), Hôpital Pitié-Salpêtrière, APHP, and Inserm U975-CRICM-Pierre and Marie Curie University, Paris; Sleep Unit (V.C.D.C., Y.D.), Department of Neurology, Hôpital Gui de Chauliac, Montpellier, INSERM U1061, Montpellier, France; Sleep Disorders Center (M.L.F.), Department of Neurosciences, University of Turin, Italy; UFR Medecine (M.L.F.), EA 7280, University Clermont 1, France; Sleep Disorders Center (L.F.-S., M.Z.), Università Vita-Salute San Raffaele, Milan, Italy; Neurology Service (A.I., J.S.), Hospital Clinic de Barcelona, IDIBAPS, CIBERNED, Spain; Department of Neurology (M.M.), Dokkyo Medical University School of Medicine, Tochigi; Department of Neurology (T.M.), Dokkyo Medical University Koshigaya Hospital, Saitama, Japan; Centre d'Études Avancées en Médecine du Sommeil (J.Y.M.), Hôpital du Sacré-Coeur de Montréal, Canada; Philipps-Universität (W.O., M.U.), Marburg, Germany; Neuroepidemiology Research Unit (A.P., C.W.), Research Institute of the McGill University Health Centre, Montreal; Canada; Unit of Sleep Medicine (P.P., M.T., R.M.), National Institute of Neurology IRCCS, C. Mondino Foundation, Pavia; Sleep Center (M.P.), Department of Cardiovascular and Neurological Sciences, University of Cagliari, Italy; Department of Neurology (K.S.), First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic; Department of Neurology (M.U.), Saarland University, Homburg/Saar; and Hephata Klinik (G.M.), Schwalmstadt-Treysa, Germany.
Abstract
OBJECTIVE: This controlled study investigated associations between comorbidity and medication in patients with polysomnographically confirmed idiopathic REM sleep behavior disorder (iRBD), using a large multicenter clinic-based cohort. METHODS: Data of a self-administered questionnaire on comorbidity and medication use of 318 patients with iRBD and 318 matched controls were analyzed. Comparisons between cases and controls were made using logistic regression analysis. RESULTS: Patients with iRBD were more likely to report depression (odds ratio [OR] 2.0, 95% confidence interval [CI] 1.3-2.9) and concomitant antidepressant use (OR 2.2, 95% CI 1.4-3.6). Subanalysis of antidepressant agents revealed that the increased use of antidepressants in iRBD was due to selective serotoninergic reuptake inhibitors (OR 3.6, 95% CI 1.8-7.0) and not due to other antidepressant classes. Patients with iRBD reported more lifetime antidepressant use than comorbid depression (antidepressant use: OR 1.9, 95% CI 1.1-3.3; depression: OR 1.6, 95% CI 1.0-2.5). Patients with iRBD reported more ischemic heart disease (OR 1.9, 95% CI 1.1-3.1). This association did not change substantially when adjusting for cardiovascular risk factors (OR 2.3, 95% CI 1.3-3.9). The use of inhaled glucocorticoids was higher in patients with iRBD compared to controls (OR 5.3, 95% CI 1.8-15.8), likely reflecting the higher smoking rate in iRBD (smoking: OR 15.3, 95% CI 2.0-118.8; nonsmoking: OR 2.4, 95% CI 0.4-13.2) and consequent pulmonary disease. CONCLUSIONS: This large study confirms the association between comorbid depression and antidepressant use in iRBD. In addition, there was an unexpected association of iRBD with ischemic heart disease that was not explained by cardiovascular risk factors.
OBJECTIVE: This controlled study investigated associations between comorbidity and medication in patients with polysomnographically confirmed idiopathic REM sleep behavior disorder (iRBD), using a large multicenter clinic-based cohort. METHODS: Data of a self-administered questionnaire on comorbidity and medication use of 318 patients with iRBD and 318 matched controls were analyzed. Comparisons between cases and controls were made using logistic regression analysis. RESULTS:Patients with iRBD were more likely to report depression (odds ratio [OR] 2.0, 95% confidence interval [CI] 1.3-2.9) and concomitant antidepressant use (OR 2.2, 95% CI 1.4-3.6). Subanalysis of antidepressant agents revealed that the increased use of antidepressants in iRBD was due to selective serotoninergic reuptake inhibitors (OR 3.6, 95% CI 1.8-7.0) and not due to other antidepressant classes. Patients with iRBD reported more lifetime antidepressant use than comorbid depression (antidepressant use: OR 1.9, 95% CI 1.1-3.3; depression: OR 1.6, 95% CI 1.0-2.5). Patients with iRBD reported more ischemic heart disease (OR 1.9, 95% CI 1.1-3.1). This association did not change substantially when adjusting for cardiovascular risk factors (OR 2.3, 95% CI 1.3-3.9). The use of inhaled glucocorticoids was higher in patients with iRBD compared to controls (OR 5.3, 95% CI 1.8-15.8), likely reflecting the higher smoking rate in iRBD (smoking: OR 15.3, 95% CI 2.0-118.8; nonsmoking: OR 2.4, 95% CI 0.4-13.2) and consequent pulmonary disease. CONCLUSIONS: This large study confirms the association between comorbid depression and antidepressant use in iRBD. In addition, there was an unexpected association of iRBD with ischemic heart disease that was not explained by cardiovascular risk factors.
Authors: Siu P Lam; Jihui Zhang; Joshua Tsoh; Shirley X Li; Crover K W Ho; Vincent Mok; Anne Y Y Chan; Yun K Wing Journal: J Clin Psychiatry Date: 2010-08 Impact factor: 4.384
Authors: Paul T Teman; Maja Tippmann-Peikert; Michael H Silber; Nancy L Slocumb; R Robert Auger Journal: Sleep Med Date: 2008-01-28 Impact factor: 3.492
Authors: Ronald B Postuma; Jean-Francois Gagnon; Maria Tuineaig; Josie-Anne Bertrand; Veronique Latreille; Catherine Desjardins; Jacques Y Montplaisir Journal: Sleep Date: 2013-11-01 Impact factor: 5.849
Authors: R B Postuma; J Y Montplaisir; A Pelletier; Y Dauvilliers; W Oertel; A Iranzo; L Ferini-Strambi; I Arnulf; B Hogl; R Manni; T Miyamoto; G Mayer; K Stiasny-Kolster; M Puligheddu; Y Ju; P Jennum; K Sonka; J Santamaria; M L Fantini; M Zucconi; S Leu-Semenescu; B Frauscher; M Terzaghi; M Miyamoto; M M Unger; V Cochen De Cock; C Wolfson Journal: Neurology Date: 2012-06-27 Impact factor: 9.910
Authors: Birgit Frauscher; Viola Gschliesser; Elisabeth Brandauer; Isabelle Marti; Martin T Furtner; Hanno Ulmer; Werner Poewe; Birgit Högl Journal: Sleep Med Date: 2010-02 Impact factor: 3.492
Authors: Ronald B Postuma; Alex Iranzo; Birgit Hogl; Isabelle Arnulf; Luigi Ferini-Strambi; Raffaele Manni; Tomoyuki Miyamoto; Wolfgang Oertel; Yves Dauvilliers; Yo-El Ju; Monica Puligheddu; Karel Sonka; Amelie Pelletier; Juan Santamaria; Birgit Frauscher; Smaranda Leu-Semenescu; Marco Zucconi; Michele Terzaghi; Masayuki Miyamoto; Marcus M Unger; Bertrand Carlander; Maria-Livia Fantini; Jacques Y Montplaisir Journal: Ann Neurol Date: 2015-03-13 Impact factor: 10.422
Authors: Ziv Gan-Or; Noreen Mohsin; Simon L Girard; Jacques Y Montplaisir; Amirthagowri Ambalavanan; Stephanie Strong; Victoria Mallett; Sandra B Laurent; Cynthia V Bourassa; Michel Boivin; Melanie Langlois; Isabelle Arnulf; Birgit Högl; Birgit Frauscher; Christelle Monaca; Alex Desautels; Jean-François Gagnon; Ronald B Postuma; Patrick A Dion; Yves Dauvilliers; Nicolas Dupre; Roy N Alcalay; Guy A Rouleau Journal: Neurobiol Aging Date: 2016-04-06 Impact factor: 4.673